VALN
Valneva SE
NASDAQ · Healthcare · Biotechnology · FR
$6.89
−2.41%Aug 14, 2026, 05:00 UTC
The European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 and will begin its assessment.
Aug 13, 2026, 05:00 UTC
Valneva SE implemented a restructuring program, with positive effects on income statement and cash flow expected in the second half of 2026.
Source:Aug 13, 2026, 05:00 UTC
Valneva SE reported its condensed consolidated financial results for the first half of 2026, provided corporate updates, and reaffirmed its financial guidance for 2026.